- Home
- SWBI vs MAZE Comparison
SWBI vs MAZE Comparison
Compare SWBI & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWBI
- MAZE
- Stock Information
- Founded
- SWBI 1852
- MAZE 2018
- Country
- SWBI United States
- MAZE United States
- Employees
- SWBI N/A
- MAZE N/A
- Industry
- SWBI Ordnance And Accessories
- MAZE
- Sector
- SWBI Industrials
- MAZE
- Exchange
- SWBI Nasdaq
- MAZE NYSE
- Market Cap
- SWBI 429.0M
- MAZE 367.0M
- IPO Year
- SWBI N/A
- MAZE 2025
- Fundamental
- Price
- SWBI $8.59
- MAZE $11.41
- Analyst Decision
- SWBI Buy
- MAZE Strong Buy
- Analyst Count
- SWBI 2
- MAZE 3
- Target Price
- SWBI $12.00
- MAZE $25.67
- AVG Volume (30 Days)
- SWBI 983.4K
- MAZE 100.1K
- Earning Date
- SWBI 06-18-2025
- MAZE 08-14-2025
- Dividend Yield
- SWBI 6.05%
- MAZE N/A
- EPS Growth
- SWBI N/A
- MAZE N/A
- EPS
- SWBI 0.30
- MAZE 0.34
- Revenue
- SWBI $474,661,000.00
- MAZE $167,500,000.00
- Revenue This Year
- SWBI $8.53
- MAZE N/A
- Revenue Next Year
- SWBI N/A
- MAZE N/A
- P/E Ratio
- SWBI $28.63
- MAZE $30.79
- Revenue Growth
- SWBI N/A
- MAZE N/A
- 52 Week Low
- SWBI $8.38
- MAZE $6.71
- 52 Week High
- SWBI $16.85
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- SWBI 33.43
- MAZE N/A
- Support Level
- SWBI $8.42
- MAZE N/A
- Resistance Level
- SWBI $10.93
- MAZE N/A
- Average True Range (ATR)
- SWBI 0.32
- MAZE 0.00
- MACD
- SWBI -0.22
- MAZE 0.00
- Stochastic Oscillator
- SWBI 6.77
- MAZE 0.00
About SWBI Smith & Wesson Brands Inc.
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.